Phase I/II Trial of Panobinostat with Lenalidomide/Bortezomib/ Dexamethasone for Transplant-Eligible Patients with Newly Diagnosed MM


Phase I/II Trial of Panobinostat with Lenalidomide/Bortezomib/ Dexamethasone for Transplant-Eligible Patients with Newly Diagnosed MM
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Noopur Raje, MD (2/17/16)
Shah JJ et al. Phase I/II trial of the efficacy and safety of combination therapy with lenalidomide/bortezomib/dexamethasone (RVD) and panobinostat in transplant-eligible patients with newly diagnosed multiple myeloma. Proc ASH 2015;Abstract 187.

Dr Raje is Director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.